[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

2 clusters · 5 sources · 3 days · First seen · Last updated

US FDA experimental treatment access debate

Overview

A debate has emerged regarding the rights of American patients to access experimental medical treatments before receiving full regulatory approval from the Food and Drug Administration (FDA).

The discussion is centered on the disparity in treatment availability between the United States and the United Kingdom. A specific case involves a 19-year-old woman from South Carolina diagnosed with glioblastoma. Although she utilized a personalized immunotherapy developed by an American company, she was required to travel to London to receive doses because licensed physicians in Britain can prescribe such therapies that have not yet received limited or trial approval in the U.S.

This situation has prompted broader arguments concerning whether patients suffering from terminal or debilitating diseases, including Alzheimer’s or Parkinson’s, should be granted earlier access to promising experimental therapies.

Entities

Food and Drug Administration · United States · University of California, Los Angeles · United Kingdom

Timeline

  1. [HEALTH] 3 sources
    FDA access to experimental cancer treatments debated

    A patient's journey to London for experimental cancer treatment highlights the regulatory differences between the FDA and UK medical practices regarding access to unapproved therapies.

  2. [HEALTH] 2 sources
    FDA access to experimental cancer treatments debated

    Advocates are calling for the FDA to allow patients access to experimental cancer treatments, noting that some Americans must travel to the UK to receive therapies not yet approved for trial use in the US.

Sources

heraldstandard.com · hotair.com · lucianne.com · opslens.com · wnd.com